Background: Many decision-analytic models with varying structures have been developed to inform resource allocation in chronic obstructive pulmonary disease (COPD). Objectives: To review COPD models for their adherence to the best practice modeling recommendations and their assumptions regarding important aspects of the natural history of COPD. Methods: A systematic search of English articles reporting on the development or application of a decision-analytic model in COPD was performed in MEDLINE, Embase, and citations within reviewed articles. Studies were summarized and evaluated on the basis of their adherence to the Consolidated Health Economic Evaluation Reporting Standards. They were also evaluated for the underlying assumptions about disease progression, heterogeneity, comorbidity, and treatment effects. Results: Forty-nine models of COPD were included. Decision trees and Markov models were the most popular techniques (43 studies). Quality of reporting and adherence to the guidelines were generally high, especially in more recent publications. Disease progression was modeled through clinical staging in most studies. Although most studies (n ¼ 43) had incorporated some aspects of COPD heterogeneity, only 8 reported the results across subgroups. Only 2 evaluations explicitly considered the impact of comorbidities. Treatment effect had been mostly modeled (20) as both reduction in exacerbation rate and improvement in lung function. Conclusions: Many COPD models have been developed, generally with similar structural elements. COPD is highly heterogeneous, and comorbid conditions play an important role in its burden. These important aspects, however, have not been adequately addressed in most of the published models.
Introduction
Predicting the outcomes of alternative scenarios and policies is a central theme in many disciplines. Epidemiological projections, such as estimating the future prevalence of a given condition, can be used as a guide for policymakers for long-term planning. Predicting costs and health consequences associated with the adoption of competing health technologies informs technology adoption and resource allocation decisions. Challenges involved in such predictions include the availability of evidence from multiple sources, the need for long-term predictions beyond available data, and the requirement for translating evidence on intermediate outcomes to policy-relevant messages. Overcoming such challenges typically requires disease simulation and decision-analytic modeling. Given that such challenges prevail in almost all contexts in health care decision making, the use of decision-analytic modeling in medical decision making is considered inevitable [1] .
The development and validation of a disease model is typically a highly complex process requiring several fundamental assumptions related to, for example, natural history, impact of the health technologies on natural history, choice of model structure, relevant time horizon for the analysis, and the outcomes of interest [2] .The next step is typically parameterization through evidence synthesis. Although it is unlikely to have a general consensus among the investigators along the process, exploring and understanding the different decisions that investigators have made in the course of developing a disease model can inform and make more comprehensive the process of subsequent model development.
The disease of focus for the present study is chronic obstructive pulmonary disease (COPD), a progressive condition of the airways characterized by diminishing lung function and episodes of symptom worsening called exacerbations [3] . At present, COPD is estimated to be the fifth cause of death worldwide, but studies project that it will become the third cause of death globally by 2030 [4] . The significant economic and humanistic burden of COPD has caused many treatments and management strategies to emerge for prevention, diagnosis, and management of the disease [5, 6] . Projection of the future burden of COPD and the requirement for economic evaluations of existing and emerging technologies have resulted in multiple COPD models. Understanding the general characteristics of such models, such as the target population, model structure, and type of questions answered, can provide future investigators with a systematic and broad view of the COPD modeling landscape.
In addition to the general features of the models, characterizing the COPD-specific assumptions made in such models can support future model development and decision analysis in terms of comprehensiveness. COPD is a remarkably heterogeneous disease [7] , which suggests that the benefits of interventions can differ among different subgroups of individuals. In addition, the devastating impact of comorbid conditions in COPD is well recognized [8] . One other potentially important assumption is how the effect of pharmacological treatments ismodeled, because clinical trials have evaluated the impact of pharmacotherapy in terms of both change in the rate of lung function decline and change in the incidence of exacerbations. Finally, there are alternative choices for modeling COPD progression; some studies model disease progression directly through the continuum of lung function, whereas others model it indirectly by translating lung function decline to discrete clinical states defined by the Global Initiative for Obstructive Lung Disease (GOLD) grades [3] .
The aim of this review was to synthesize the state of science in the field by systematically exploring the characteristics of COPD models. Our review considered adherence to the best practice modeling guidelines as well as the assumptions made in COPD models relating to specific aspects of the disease. We were interested in finding the areas of similarity as well as differences across published COPD models in search of opportunities for potential improvement in decision-analytic modeling in the field of COPD.
Methods
A systematic review was undertaken on the basis of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [9] . We performed a search in MEDLINE and Embase (completed on August 24, 2015) limited to articles in English. In addition, we performed manual searches on the reference lists of the included articles and consulted with experts for relevant publications. Details of the literature search are provided in Appendix I in Supplemental Materials found at http://dx.doi. org/10.1016/j.jval.2016.08.003.
Studies that met the inclusion criteria were those that used a formal decision-analytic modeling approach to project the future burden of COPD or were studies that undertook a costeffectiveness analysis of alternative interventions. Only studies with a primary focus on COPD were considered; therefore, publications considering COPD as an event or a complication of another condition were excluded.
Study selection was carried out in two phases. First, title and abstract screening was performed, independently and in duplicate, by the primary reviewer (Z.Z.) and then a secondary reviewer (T.C. or M.S.). Discrepancies between reviewers' findings were discussed and resolved through consensus. Second, fulltext analysis was performed by the primary reviewer, who identified the final set of studies to be included in the analysis. A customized checklist was created to summarize key parameters of all simulation models. A second reviewer (A.K.) independently extracted data from a random selection (10%) of studies to ensure consistency in data extraction. Key information from the reviewed articles was extracted and categorized according to the following three groups: adherence to guidelines, model lineage (i.e., further development of a previously published model), and COPD assumptions.
General Characteristics and Adherence to Reporting Guidelines
We summarized the general characteristics of the models using a modified checklist that was initially based on a previously published study [10] . It included the target jurisdiction (country), authors, year of publication, type of model (models were classified according to published taxonomies [11] , summarized in Table 1 ), intervention, type of population (static population, which is the evolution of a fixed cohort, and dynamic[or open] population, which incorporates arrival of new individuals during the study period), time horizon, cycle length (if applicable), perspective of the evaluation (e.g., third-party or societal), discount rate, how effect measure was modeled (if applicable), and whether indirect costs were included.
We also evaluated the adherence of models to the health economic modeling report guidelines: the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) [2] .
Model Lineage
Often, disease models, once developed, are used for various purposes over time. This involves rounds of model expansion and revisions, generating various model versions based on the same model structure. Studying the evolution or lineage of such models over time provides another means for mapping the COPD modeling landscape. On the basis of statements made by authors and works cited in the articles, we mapped the lineage or history of the models.
Exploration of COPD-Specific Assumptions
We explored the COPD-specific elements of each model with a focus on the areas of active research in COPD, which were defined by the expert clinician of our team. The first criterion considered was COPD progression. This could be modeled in terms of transition either through severity stages (e.g., GOLD grade) or through continuous changes in lung function metrics (e.g., forced expiratory volume in 1 second [FEV 1 ]). Although GOLD grades are mainly based on FEV 1 cutoffs, a fixed transition rate across GOLD grades does not necessarily correspond to a fixed rate of FEV 1 decline. The second criterion was the impact of pharmacotherapy in terms of assumptions about the impact of treatment on lung function or exacerbation rate. Given that exacerbation is a function of COPD severity (lung function), modeling treatment effect on lung function indirectly affects exacerbation rates. Many studies, however, have reported the direct impact of pharmacotherapy on exacerbation rates, which might not necessarily be mediated through lung function. Furthermore, the assumptions regarding heterogeneity in the natural history of COPD were investigated. Studies were assessed in terms of whether they incorporated heterogeneity in model calculations and whether they reported results across subgroups. Finally, we determined whether COPD comorbidities were considered explicitly in the model.
Results
The search resulted in 4054 references, excluding duplicates. During title and abstract screening, 3911 citations were excluded, resulting in 143 articles for full-text analysis. The agreement between reviewers in the screening process was very good (κ statistic 0.89) [12] . After full-text review,49 publications met the inclusion criteria ( Fig. 1 ) [9] . Table 2 presents a summary of the 49 models. A wide range of simulation modeling approaches had been applied: 41 studies were Markov models , 2 were decision trees [54, 55] , 1 used a time-in-state model [56] , 2 used an individual sampling modeling approach [57, 58] , 1 was a discrete-event simulation [59] , and 2 were system dynamics models [60, 61] .
Summary of General Characteristics of Models and Their Adherence to CHEERS
Most of the models (n ¼ 40) were developed for the purpose of economic evaluation, either of alterative COPD treatments or of a COPD management program [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [24] [25] [26] [27] [28] [30] [31] [32] [33] [34] [37] [38] [39] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [54] [55] [56] 58, 60, 61] . Two models [40, 41] were developed to project the future burden of COPD; five models [23, 29, 35, 36, 53] represented a case study for methodological work; and two models [57, 59] were developed as a generic modeling framework (multipurpose and not an ad hoc model). Seven models [16, 33, 40, 41, 49, 60, 61] were open population (dynamic) models. Table 3 presents the results of the assessment of adherence to the CHEERS guideline [2] . Studies generally did well in following the reporting guideline (even though several articles did not explicitly state adherence to CHEERS or any other guideline). Nevertheless, the reporting of some items was commonly neglected, such as details of the analytical methods (only 34 articles explicitly described the analytical methods), reporting of probabilistic distributions along with their parameters (only 25 articles comprehensively mentioned deterministic and probabilistic distributions of parameters), and the evaluation of heterogeneity through subgroup-specific results (only 8 articles reported the results per subgroup). Figure 2 depicts the lineage of all the published models. As can be seen, a Markov model by Oostenbrink et al. [24] , which was developed for the Netherlands and Canada, was the most widely adopted model structure, used in eight subsequent studies (seven for European jurisdictions and one not explicitly mentioning its jurisdiction). Other widely adopted model structures were from Borg et al. [13] , Price et al. [15] , Spencer et al. [18] , Hoogendoorn et al. [33] , Sin et al. [37] , Buist et al. [40] , and Asukai et al. [57] . These adopted models, along with their "offspring," are presented in Figure 2 .
Model Lineage

Review of Models with Regard to COPD-Specific Features
In terms of modeling COPD progression, 41 studies 46, 48, 49, [51] [52] [53] 56, 60, 61] modeled transition across GOLD grades, whereas only 2 studies [57, 58] modeled progression through FEV 1 decline. FourMarkov models [45, 47, 54, 55] used exacerbation status in defining model states, and 1study modeled COPD through states defined by the maintenance therapy usage [50] . One study [59] did not clearly mention how the authors modeled the disease progression.
For the most part, treatment effect was modeled as a direct reduction in exacerbation rate without any impact on lung function [20, 21, 32, [34] [35] [36] [37] [38] [39] [44] [45] [46] 50, 52, 54, 55] . Several other studies, however, modeled the impact of treatment in improving lung function either without [14, 33, 42, 43, 51, 53, 56] 
Type of model Description
MM MMs consist of a set of mutually exclusive states that patients can transition between at a cycle [11] . MMs are mostly used to project the trajectory of a cohort of individuals over time, through which between-individual variation (i.e., heterogeneity) is usually forgone. MMs are very popular for disease modeling because of their simplicity of implementation. Nevertheless, two disadvantages attached to MMs are 1) the Markovian assumption underlying MMs that expresses that the future states depend only on present states and 2) MMs are not fully capable of reflecting an individual's trajectory over time (even if they are used to model individuals rather than a cohort, they give the probability of an individual being at different states at a cycle rather than a specific state for that individual to be at that cycle). DT DT is a simulation technique in which an individual or a cohort of individuals can move to different states, or different events might occur with different probabilities [4] . DTs are intrinsically close to MMs with the difference that unlike MMs they are untimed [4] . Although the implementation of a DT model is straightforward, the fact that time is essentially ignored in a DT model is its biggest drawback. DES DES is a simulation technique in which the agent of a model is an individual rather than a cohort, with possible interaction between agents of the model [11] . DES is a capable framework for reflecting between-individual variation (i. e., heterogeneity) and modeling the trajectory of an individual over time [11] . Nevertheless, probabilistic implementation of such models requires a high computational capacity. ISM ISM is similar to DES when the agent of a model is an individual; nevertheless, unlike DES, there is no interaction between the model's agents in ISM [11] . SD SD is another simulation technique for modeling a cohort, through which differential equations inform the present states within the model [11] . SDs are not capable of modeling heterogeneity and their probabilistic implementation requires high computational capacity. TSM TSM has a similar concept as an MM because there are some mutually exclusive states that at each cycle contain a proportion of the cohort [56] . The difference between TSM and MM is that there are no transition probabilities in TSM, which simply relaxes the underlying Markovian assumption of MMs.
DES, discrete-event simulation; DT, decision tree; ISM, individual sampling model; MM, Markov model; SD, system dynamics; TSM, time-instate modeling.
however, was mostly modeled through a one-time jump in lung function at the beginning of therapy. One study [61] modeled treatment effect through direct reduction in disease mortality and disability. Three studies [27, 47, 59] did not clearly mention how the effect of treatments was modeled.
Most studies incorporated at least some aspects of disease heterogeneity into their main analysis through subgroup-level stratification. The most popular subgroup variables were baseline disease severity, sex, and age. Nevertheless, only eight studies [22, 23, 32, 33, 41, 42, 51, 60] clearly reported results of subgroupspecific analyses.
Only two models, those by Lock et al. [14] and Zaniolo et al. [46] , explicitly incorporated the impact of comorbidities. The former evaluated the cost-effectiveness of smoking cessation, and the latter the cost-effectiveness of tiotropium bromide. In both studies, the authors acknowledged the importance of comorbid conditions in the context of their evaluation. Some other models indirectly considered the impact of comorbidity. Price et al. [58] mentioned comorbidity as a predictor for calculating utility values. In the study by Bilge and Saka [59] , comorbidity was mentioned to be "a variable in the model; nevertheless, the exact nature and impact of such a variable were not discussed explicitly.
Discussion
We performed a systematic review of simulation models of COPD that have been used for burden of disease projections or economic evaluation of interventions and programs for COPD. Our systematic review identified 49 models. There are some general similarities among the studies. For example, most of the studies (n ¼ 43) used a Markov modeling approach. Modeling the progression of COPD on the basis of transition through established clinical grading systems was a common feature. There was, however, greater heterogeneity in modeling the specific aspects of COPD including assumptions of treatment effects and disease progression. Generally, models did well in complying with the standard modeling reporting guidelines.
There were some limitations in our study. First, only English articles were included in our search. Second, model development is a very complex process containing many elements ranging from evidence synthesis to deciding on underlying assumptions to identify the relevant outcomes. Describing all such elements in detail in a single article is not feasible. As such, there has been a certain level of subjectivity in our assessment of published models. A more comprehensive assessment of models would involve access to the models' codes and requesting additional details from the authors. Running identical scenarios on different models as well as enabling or disabling some of the model features would provide critical insight into the impact of different assumptions on the variability in the reported results.
Several models had included some aspects of heterogeneity in the natural history of COPD, mainly through stratification of analysis on patient characteristics. Nevertheless, given the extent of heterogeneity in the natural history of COPD, and that only a fraction of such heterogeneity can be explained by observable traits [62, 63] , our conclusion is that heterogeneity was not fully Price et al (15) Ariza et al (16) Price et al (17) Spencer et al (18) Sun et al (19) Hertel et al (20) Samyshkin et al (21) Samyshkin et al (22) Vemer et al (23) Oostenbrink et al (24) Maniadakis et al (25) van Molken et al (26) Oostenbrink et al (27) Gani et al (28) Oppe et al (29) HeƩle et al (30) Hoogendoorn et al (31) Hoogendoorn et al (32) Hoogendoorn et al. (33) van Boven et al (34) Zafari et al (35) Thorlund et al (36) Sin et al (37) Earnshaw et al (38) Chuck et al (39) Buist et al (40) Nielsen et al (41) Atsou et al (42) Oba et al (43) Oba et al (44) Liu et al (45) Zaniolo et al (46) Jubran et al (47) Chandra et al (48) Hoogendoorn et al (49) Naik et al (50)
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accounted for. In cohort models (e.g., Markov models), violation of the homogeneity principle can cause bias in the estimated outcomes, even when the outcome of interest is costeffectiveness for the whole population [64] . Cohort models should be stratified on subgroups such that each subgroup can be considered a homogeneous population. If the creation of many subgroups is required to account for heterogeneity, then cohort models can become unwieldy. In such instances, the use of microsimulation (individual-level modeling) is recommended [11] . In addition to this technical requirement, we think there are other reasons to encourage the use of microsimulations. As the emphasis on individualizing care (personalized medicine) gains momentum, so should the analytical platforms for evaluation of individualized care. Individual-level modeling has the capacity to provide results that can guide decision making for individual patients on the basis of his or her clinical traits. Individual-level models provide an ideal framework for modeling heterogeneity that is not accounted for by observable traits (e.g., through assigning random-effect terms to simulated individuals). It is, however, important to note that implementing such individual-level modeling would, generally, come with more complexity and a longer development time.
Another important aspect of the burden of COPD that was largely ignored in the published models is comorbidity [8] . For many interventions, such as smoking cessation, the need for the incorporation of other diseases that are affected by smoking is clear. Nevertheless, even for interventions such as pharmacotherapy for COPD, the impact of considering comorbid conditions is likely to be substantial. Evidence suggests that the degree of lung function impairment is correlated with the incidence of comorbid conditions, and there is an intricate bidirectional causal relationship between comorbid conditions such as heart failure and COPD exacerbations [65] . As such, impact of an intervention targeted at COPD can be multifaceted. This is an area of future research in terms of both a better understanding of the causal relationships between COPD and comorbid conditions and the impact of such considerations in COPD models in terms of their results.
Conclusions
Many COPD models have been developed, generally with similar structural elements. Nevertheless, modeling practice in COPD is in need of improvement to more fully acknowledge the highly heterogeneous nature of the disease and the fact that comorbid conditions play an important role in its burden. These critical 
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